It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

AstraZeneca gets US clearance for Alexion acquisition

Fri 16 April 2021 12:04 | A A A

No recommendation

No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.

(Sharecast News) - AstraZeneca has received US clearance for its proposed acquisition of Alexion Pharmaceuticals.

The company said on Friday that the deal has now cleared the US Federal Trade Commission review.

The acquisition has already received regulatory clearance in Canada, Brazil, and Russia, among others. Additional regulatory clearances are pending, including the UK, EU and Japan.

Marc Dunoyer, executive director and chief financial officer of AstraZeneca, said: "These clearances further advance us towards closing our acquisition of Alexion. We remain focused on the next chapter for AstraZeneca and Alexion, building on our combined expertise in immunology and precision medicines and our shared ambition to bring more innovative medicines to patients worldwide."

The pharmaceuticals giant announced in December 2020 that it had agreed to buy Alexion in a $39bn deal to expand its scientific presence in immunology. It said at the time that the deal was expected to close in the third quarter of 2021.

    The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.


    More company news from ShareCast